Management's discussion and analysis of results of operations and financial condition highlights the various risks and uncertainties that may cause actual results to differ materially from forward-looking statements. The company emphasizes its ability to respond effectively to environmental disruptions and transform itself to emerge stronger from challenging situations. The ongoing covid-19 pandemic has adversely impacted the business and operations across markets to varying degrees, including cost inflation and strain on global transportation, manufacturing, and labor markets. The company has focused on protecting the health and safety of its employees while supporting the medical system and communities, demonstrating its commitment to organizational resilience. The impact of competition and pricing pressure, particularly following the expiration of patent exclusivity for certain products, has rapidly eroded revenue, necessitating strategic responses to maintain operational continuity and performance. The company has undertaken compensatory actions to improve retention and address wage inflation, which will increase compensation costs and impact consolidated results of operations. Investments in manufacturing capacity are being made to meet existing and expected demand, reflecting a proactive approach to resource allocation and operational flexibility. The company recognizes the importance of maintaining a robust pipeline of innovative new medicines, which is crucial for long-term success and organizational health. The management continuously evaluates liquidity and capital resources to ensure adequate financing for capital requirements, including working capital, capital expenditures, and potential business development activities. The company has recognized significant charges related to asset impairment and restructuring, indicating the need for adaptability in response to changing market conditions. The management's focus on research and development underscores the commitment to innovation and the ability to absorb strain while preserving functionality. The establishment of payment limits or other restrictions by drug affordability review boards may impact the business, necessitating strategic initiatives to navigate these challenges. The company faces foreign currency risk exposure from fluctuating exchange rates and seeks to manage these risks through hedging and other risk management techniques. The ongoing evaluation of operational resources and strategic planning is essential to address uncertainties and maintain performance under pressure. The company acknowledges the complexities and challenges inherent in pharmaceutical research and development, which require a multifaceted approach to ensure resilience and adaptability in a turbulent market environment. The management's focus on inter-organizational collaboration and strategic foresight is vital for navigating external pressures and ensuring organizational success.